By Sharecast
Date: Monday 22 Dec 2025
By Josh White
Date: Thursday 04 Sep 2025
(Sharecast News) - Oxford BioDynamics said on Thursday that interim results from its ongoing FDA-registered PROWES trial demonstrated that its EpiSwitch CiRT test had a significant impact on treatment decisions for cancer patients receiving immune checkpoint inhibitors.
By Josh White
Date: Wednesday 13 Aug 2025
(Sharecast News) - Oxford BioDynamics announced a collaboration with Google Cloud on Wednesday, to accelerate the development and deployment of its cloud-based analytical framework for precision medicine.
| Currency | UK Pounds |
| Share Price | 0.19p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 0.60 |
| 52 Week Low | 0.17 |
| Volume | 4,858,067 |
| Shares Issued | 4,290.91m |
| Market Cap | £7.94m |
| Beta | 0.01 |
| Value | ![]() |
|---|
| Price Trend | ![]() |
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:29 | 271,733 @ 0.18p |
| 15:47 | 50,000 @ 0.17p |
| 15:38 | 52,179 @ 0.18p |
| 13:59 | 160,710 @ 0.17p |
| 13:09 | 20,084 @ 0.20p |
You are here: research